Evropská unie - řečtina - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - Μυϊκή ατροφία, σπονδυλική στήλη - Άλλα φάρμακα για διαταραχές του μυοσκελετικού συστήματος - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Evropská unie - řečtina - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - Ανοσοκατασταλτικά - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Evropská unie - řečtina - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - Άνοσοι οροί και ανοσοσφαιρίνες, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. Βλ. Ενότητες 4. 4 και 5.

Evropská unie - řečtina - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - Καρκίνωμα, μη μικροκυτταρικός πνεύμονας - Αντινεοπλασματικοί παράγοντες - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Evropská unie - řečtina - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - Λέμφωμα, θυλακοειδής - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Evropská unie - řečtina - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - Οφθαλμολογικά - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Evropská unie - řečtina - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

ΙΦΕΤ ΑΕ 18ο χλμ. Λεωφ. Μαραθώνος,, 153 51 153 51, Παλλήνη Αττικής 210.6603400-6603522 - neostigmine metilsulfate - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 0,5mg/1ml - neostigmine metilsulfate - neostigmine

Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

ΙΦΕΤ ΑΕ 18ο χλμ. Λεωφ. Μαραθώνος,, 153 51 153 51, Παλλήνη Αττικής 210.6603400-6603522 - procarbazine hydrochloride - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 50mg/cap - procarbazine hydrochloride - procarbazine

Řecko - řečtina - Εθνικός Οργανισμός Φαρμάκων

ΙΦΕΤ ΑΕ 18ο χλμ. Λεωφ. Μαραθώνος,, 153 51 153 51, Παλλήνη Αττικής 210.6603400-6603522 - sulfadoxine; pyrimethamine - tab (ΔΙΣΚΙΟ) - 500+25 mg/tab - sulfadoxine; pyrimethamine - pyrimethamine, combinations